Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Journal of Geriatric Psychiatry and Neurology|November 7, 2006
Predicting lewy body pathology in a community-based sample with clinical diagnosis of Alzheimer's diseaseDebby Tsuang, Kate Simpson, Eric B Larson, et al.
Autism Research : Official Journal of the International Society for Autism Research|June 6, 2022
Patterns of sensory modulation by age and sex in young people on the autism spectrumAlison E Lane, Kate Simpson, Anne Masi, et al.
Implementation Science : IS|October 5, 2011
Design, rationale, and baseline characteristics of a cluster randomized controlled trial of pay for performance for hypertension treatment: study protocolLaura A Petersen, Tracy Urech, Kate Simpson, et al.
Bulletin of the World Health Organization|October 25, 2003
Injury prevention counselling to improve safety practices by parents in MexicoCharles Mock, Carlos Arreola-Risa, Rodolfo Trevino-Perez, et al.
The American Journal of Pathology|July 9, 2018
Association of Elevated Urinary miR-126, miR-155, and miR-29b with Diabetic Kidney DiseaseCristina Beltrami, Kate Simpson, Mark Jesky, et al.
European Journal of Cancer (Oxford, England : 1990)|October 14, 2021
Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in children with multiple endocrine neoplasia type 2 and advanced medullary thyroid carcinomaAnanth Shankar, Tom Kurzawinski, Emma Ross, et al.
Scientific Reports|August 14, 2021
miR-141 mediates recovery from acute kidney injuryLucy J Newbury, Kate Simpson, Usman Khalid, et al.
Pilot and Feasibility Studies|January 8, 2026
Protocol for a feasibility and acceptability trial of Bloom, a co-produced and co-facilitated parent group to enhance the quality of life and well-being of young autistic childrenDawn Adams, Kathryn Ambrose, Rachael Bowen, et al.
Scientific Reports|September 9, 2017
In search of a small molecule agonist of the relaxin receptor RXFP1 for the treatment of liver fibrosisAndrew McBride, Anna M Hoy, Mark J Bamford, et al.
Therapeutic Advances in Chronic Disease|August 21, 2023
Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopeniaSaskia Inniss, Konstantinos C Fragkos, Lisa Whitley, et al.
Pageof 8